Bioxyne Limited (ASX:BXN) Amendment Announcement

Bioxyne Limited (ASX:BXN) has finalized an amendment to an existing manufacturing and supply agreement with Aura Therapeutics, a well-established Australian medicinal cannabis sponsor and distributor. The amendment allows Breathe Life Sciences (BLS), a wholly owned subsidiary of Bioxyne, to manufacture edible cannabis pastilles and double the existing THC Flower product volumes. Based on the agreement and forecast volumes, BLS anticipates generating up to $5.94 million in sales on an annualized basis, with pastilles contributing $3.14 million and THC Flower Products contributing $2.80 million.

Executive Commentary on Amendment

Sam Watson, Founder & CEO of BLS and Managing Director of BXN, expressed pride in being the trusted manufacturing partner for companies like Aura Therapeutics. The amendment signifies Bioxyne's commitment to supplying Australian-made pharmaceutical goods to domestic and international markets, particularly in the cannabis products sector.

Summary of Bioxyne's Amendment Announcement

Bioxyne Limited (ASX:BXN) has solidified its position as a leading manufacturer and supplier of alternative pharmaceuticals, including cannabis products, Psilocybin, and MDMA for authorized prescribers and clinical trials in domestic and international markets. The amendment to the manufacturing and supply agreement with Aura Therapeutics is expected to significantly boost sales, with pastilles and THC Flower Products contributing to an estimated annual revenue of $5.94 million. With the comprehensive GMP license for cannabis products, Bioxyne is well-positioned to capitalize on the emerging domestic market opportunity and further establish itself as a substantial proponent in the Australian pharmaceutical manufacturing and medical cannabis industry. The company's focus on building strong ties with customers and providing high-quality GMP-certified manufacturing services reflects its commitment to becoming a leading manufacturer and supplier of GMP-certified cannabis, MDMA, and psilocybin products in Australia and global export markets.